Christopher Posner sold $2,769 of TVRD
PRESIDENT AND CEO at Cara Therapeutics, Inc.. 583 shares at an average of $4.75, traded Feb 28, 2025, filed Mar 4, 2025.
Score components
- +25RoleCEO
- 0Trade size$3k at market
- 0Share of holdings soldSold 4.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +11.7%, 3m +99.5%, 6m +122.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-006576, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 28, 2025 | SOpen-market sale Common Stock10b5-1 | -583 | $4.75 | $2,769 | 13,109 | Mar 4, 2025 |
Related signals
Other insiders at Cara Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Cara Therapeutics, Inc. | Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | $776 163 shares | -2% | |
| 5Weak | Cara Therapeutics, Inc. | Christopher Posner PRESIDENT AND CEO | $1,756 372 shares | -3% | |
| 5Weak | Cara Therapeutics, Inc. | Christopher Posner PRESIDENT AND CEO | $1,064 3,668 shares | -2% | |
| 5Weak | Cara Therapeutics, Inc. | Christopher Posner PRESIDENT AND CEO | $2,952 3,936 shares | -2% | |
| 3Weak | Cara Therapeutics, Inc. | Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | $2,285 2,753 shares | -3% | |
| 3Weak | Cara Therapeutics, Inc. | Joana Goncalves CHIEF MEDICAL OFFICER | $2,285 2,753 shares | -5% | |
| 10Weak | Cara Therapeutics, Inc. | Joana Goncalves CHIEF MEDICAL OFFICER | $2,931 3,293 shares | -6% | |
| 20Weak | Cara Therapeutics, Inc. | Christopher Posner PRESIDENT AND CEO | $5,192 5,834 shares | -3% | |
| 10Weak | Cara Therapeutics, Inc. | Scott Terrillion SEC'Y; CHIEF COMPLIANCE & G.C. | $2,931 3,293 shares | -3% | |
| 10Weak | Cara Therapeutics, Inc. | Christopher Posner PRESIDENT AND CEO | $19k 35,575 shares | -16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.